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Macrocyclisation of Small Peptides Enabled by Oxetane 
Incorporation†
Stefan Roesner,‡ George J. Saunders,‡ Ina Wilkening,‡ Eleanor Jayawant, Joanna V. Geden, Paul 
Kerby, Ann M. Dixon, Rebecca Notman and Michael Shipman*
Cyclic peptides are an important source of new drugs but are challenging to produce synthetically. We show that head-to-
tail peptide macrocyclisations are greatly improved, as measured by isolated yields, reaction rates and product 
distribution, by substitution of one of the backbone amide C=O bonds with an oxetane ring. The cyclisation precursors are 
easily made by standard solution- or solid-phase peptide synthesis techniques. Macrocyclisations across a range of 
challenging ring sizes (tetra-, penta- and hexapeptides) are enabled by incorporation of this turn-inducing element. 
Oxetane incorporation is shown to be superior to other established amino acid modifications such as N-methylation. The 
positional dependence of the modification on cyclisation efficiency is mapped using a cyclic peptide of sequence LAGAY.  
We provide the first direct experimental evidence that oxetane modification induces a turn in linear peptide backbones, 
through the observation of dNN (i, i+2) and dN (i, i+2) NOEs, which offers an explanation for these improvements. For 
cyclic peptide, cLAGAY, a combination of NMR derived distance restraints and molecular dynamics simulations are used to 
show that this modification alters the backbone conformation in proximity to the oxetane, with the flexibility of the ring 
reduced and a new intramolecular H-bond established. Finally, we incorporated an oxetane into a cyclic pentapeptide 
inhibitor of Aminopeptidase N, a transmembrane metalloprotease overexpressed on the surface of cancer cells. The 
inhibitor, cCNGRC, displayed similar IC50 values in the presence or absence of an oxetane at the glycine residue, indicating 
that bioactivity is fully retained upon amide C=O bond replacement.                                                              . 
Introduction
Currently more than 40 cyclic peptide drugs are in clinical use 
with the vast majority derived from natural products (e.g. 
cyclosporine, vancomycin).1 Compared to their linear 
counterparts, cyclic peptides benefit from enhanced cell 
permeability, increased target affinity, and resistance to 
proteolytic degradation.2 Moreover, they are capable of acting 
as inhibitors against some of the most challenging targets, 
including protein-protein interactions (PPIs).3 One major 
obstacle to the discovery and development of new cyclic 
peptide drugs relates to the difficulties associated with their 
synthesis.4 The head-to-tail cyclisation of short peptides 
containing seven or fewer amino acids is especially 
challenging. Common problems encountered during cyclisation 
are C-terminal epimerisation, cyclooligomerisation and the 
appearance of side products arising from polymerisation 
(Scheme 1). Consequently, there is a pressing need to discover 
new macrocyclisation strategies that can provide easy access 
to a variety of small cyclic peptide scaffolds suitable for use in 
drug discovery programmes.5 
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Scheme 1 Difficulties associated with making small cyclic peptides and improvements 
arising from oxetane introduction.
The incorporation of turn-inducing elements such as a 
pseudoproline, an N-alkylated or a D-amino acid into a linear 
peptide often enhances peptide macrocyclisations.4c,6 Recently 
we have shown that substitution of a backbone amide C=O 
with an oxetane ring induced turns in tripeptides,7 suggesting 
that oxetane introduction into the backbone of a linear 
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peptide might offer a general method to improve 
macrocyclisation efficiency by promoting conformational 
preorganisation of the linear peptide such that the C- and N-
termini are brought into close proximity (Scheme 1). 
Importantly, the use of oxetanes as bioisosteres in small-
molecule drug discovery is well established,8 with emerging 
applications in peptide science.9,10 For example, the grafting of 
oxetanes onto the cysteine side chains of proteins and 
antibodies can significantly improve their stability and 
activity.9 Additionally, the serum half-life and in vivo analgesic 
properties of linear peptides such as Leu-enkephalin can be 
improved by introduction of an oxetane.10 
In this Edge Article, we show that many peptide 
macrocyclisations can be greatly improved by oxetane 
incorporation, and that the resulting modified peptides are 
biologically active, supporting the hypothesis that oxetane 
modified cyclic peptides (OMCPs) represent a powerful new 
class of peptidomimetic for drug discovery.
Results and discussion
Synthesis of oxetane modified cyclisation substrates
To study the impact of oxetane modification on peptide 
macrocyclisation efficiency, a range of linear peptide 
precursors were synthesised. Many of the substrates were 
made in solution using Bn ester/Z-protection of the C- and N-
termini to allow the synthesis of salt-free precursors by use of 
a final hydrogenolysis step. This enabled accurate comparisons 
in product yields to be made across different substrates 
without having to correct for the impact of salts on the 
cyclisations. The synthesis of oxetane modified peptides was 
also achieved using the more practical approach of solid-phase 
peptide synthesis (SPPS). In most cases, control peptides 
without the oxetane modification were made for comparison 
purposes (see ESI).
Two distinct methods were used to make the linear 
peptides. In the first, oxetane introduction was achieved by: (i) 
conjugate addition of the N-terminus of the growing peptide 
to 3-(nitromethylene)oxetane; (ii) nitro group reduction and in 
situ coupling of the resulting amine to the next protected 
amino acid, preactivated as its succinyl ester.7,11 This method 
proved very convenient for the solution-phase synthesis of 
oxetane modified glycine residues as illustrated by the 
preparation of pentapeptide 1 (Scheme 2). Alternatively, 
preformed Fmoc-protected dipeptide building blocks 
containing the oxetane modification were incorporated into 
the growing peptide chain as shown for the synthesis of 
pentapeptide 2 (Scheme 3). This second method is suitable for 
the introduction of oxetane modified derivatives of other L-
amino acids,10 is fully compatible with standard Fmoc/tBu 
SPPS,11a and avoids the need to subject the growing peptide 
chain to strongly reductive conditions. The assembly of resin-
bound tetrapeptide 17 by SPPS provides an illustration of the 
utility of this method (Scheme 4), with additional examples in 
the ESI. 
Scheme 2 Synthesis of oxetane modified pentapeptide 1. Reagents and conditions: (a) 
TFA/CH2Cl2 (1:1), 1 h; (b) (i) oxetan-3-one (2.0 equiv), MeNO2 (2.8 equiv), Et3N (0.4 
equiv), 0 °C to RT, 1 h; (ii) MeSO2Cl (2.0 equiv), Et3N (4.0 equiv), CH2Cl2, –78 °C, 1.5 h; 
(iii) amine from (a), Et3N (1.5 equiv), –78 °C to RT, 16 h; (c) Raney Ni, H2, Boc-Ala-OSu 
(1.5 equiv), THF, 4 h; (d) TFA/CH2Cl2 (1:1), 1 h; (e) Cbz-Leu-OH (1.1 equiv), EDC∙HCl (1.1 
equiv), HOBt∙H2O (1.1 equiv), NMM (4.0 equiv), CH2Cl2, 24 h; (f) 10% Pd/C, H2, MeOH, 
16 h.
Scheme 3  Synthesis of pentapeptide 2 using oxetane containing dipeptide building 
block. Reagents and conditions: (a) 2% TFA/CH2Cl2, 2 h; (b) H-Cys(Trt)-OtBu (1.5 equiv), 
HATU (1.1 equiv), iPr2EtN (4.0 equiv), DMF, 48 h; (c) Et2NH/CH2Cl2 (1:1), 1 h; (d) Fmoc- 
Asn(Trt)-OH (1.5 equiv), HATU (1.5 equiv), iPr2EtN (3.0 equiv), CH2Cl2, 16 h; (e) 
Et2NH/CH2Cl2 (1:1), 1 h; (f) Boc-Cys(Trt)-OH (1.4 equiv), HATU (1.4 equiv), iPr2EtN (3.0 
equiv), CH2Cl2, 16 h.
Macrocyclisation of oxetane modified pentapeptides
To study the impact of oxetane introduction on the 
efficiency of macrocyclisation, ring closure of the pentapeptide 
LAGPY in the presence and absence of oxetane modified 
glycine was studied under a variety of conditions. As shown in 
Table 1 (entries 6–8), this substrate was chosen because 
cyclisation of the corresponding unmodified pentapeptide is 
very low yielding (13-23%) even under high dilution.12 Upon 
introduction of the oxetane modification, a 3-fold yield 
improvement was observed. The best yield was obtained using 
PyBOP (Table 1, entry 3), although DEPBT and HATU were also 
efficient with similar levels of improvement seen. Later studies 
exploring the wider scope of this methodology led us to favour 
DEPBT as the reagent of choice in most cases. Of practical 
importance, the reaction can be conducted on a larger scale 
(0.5 mmol) under less dilute conditions (0.005 M) without loss 
of yield (Table 1, entry 1). 
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Table 1 Impact of oxetane modification on the cyclisation efficiency of a pentapeptide.
Entry Substratea Coupling 
reagentb
Product Yield (%)c
1 1 DEPBT 4 48 (50)d
2 1 DEPBTe 4 33
3 1 PyBOP 4 60
4 1 HATU 4 53
5 1 T3P 4 28
6 3 DEPBT 5 13f
7 3 PyBOP 5 23
8 3 HATU 5 15
a All reactions run on 0.1 mmol scale. b 3-(Diethoxyphosphoryloxy)-1,2,3-benzotriazin-
4(3H)-one (DEPBT); O-(7-azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium 
hexafluorophosphate (HATU); (benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate (PyBOP); propylphosphonic anhydride (T3P). c Isolated yield after 
column chromatography. d Yield in parenthesis relates to larger scale reaction (0.5 
mmol) run at higher concentration (0.005 M). e iPr2EtN omitted. f Taken from ref 12.
Insights into the impact of oxetane introduction on the 
efficiency of this macrocyclisation were revealed by LC-MS 
analysis (Figure 1). In the cyclisation of the unmodified 
peptide, there are significant quantities of unreacted linear 
pentapeptide 3 left even after 48 h. Additionally, linear and 
cyclic decapeptides arising from substrate dimerisation were 
evident alongside a second cyclic pentapeptide arising from C-
terminal epimerisation (Figure 1, bottom). In contrast, for the 
oxetane containing precursor, essentially complete 
consumption of starting material is seen on this timescale. The 
reaction is also much cleaner with the corresponding by-
products seen in only trace quantities (Figure 1, top). Thus, 
significant improvements in this difficult macrocyclisation are 
realised through introduction of the oxetane motif.
To gain a deeper understanding of reaction rates and the 
products formed, time-course studies of an inherently difficult 
to cyclise tetrapeptide WLGG (6) and corresponding oxetane 
modified WLGOxG (7) (where GOx = oxetane modified glycine) 
were undertaken. For this investigation, substrates containing 
a tryptophan residue were used to allow quantitative 
monitoring by UV spectroscopy. Both substrates were 
subjected to the DEPBT method and conversions monitored 
over 74 h. From these data, it is clear that the initial rate of 
formation of oxetane containing cyclic peptide 9 is 
considerably faster than 8, even though both linear precursors 
6 and 7 are consumed at similar rates (Figure 2). The isolated 
yields for these macrocyclisations are given in Figure 3 and 
again demonstrate the benefits of the oxetane motif. 
Appreciable quantities of the unwanted dimer and cyclodimer 
were produced in the cyclisation of 8, explaining the lower 
conversion and isolated yield (see ESI). In contrast, for the 
oxetane-modified peptide 7 clean conversion to the cyclic 
product 9 was observed. Taken together, these studies 
establish that head-to-tail ring closures to form small cyclic 
peptides proceed more quickly, give higher yields and produce 
less side products when one of the backbone carbonyl groups 
is replaced by an oxetane ring.
Figure 1 Extracted ion chromatograms of peptide macrocyclisations [DEPBT (2 equiv), 
iPr2EtN (2 equiv), DMF (0.001 M), 48 h, RT] for 1  4 (top) and 3  5 (bottom).
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Figure 2 Impact of oxetane modification on macrocyclisation rates: Cyclisation of WLGG 
(6) and oxetane modified WLGOxG (7) monitored over 74 h using DEPBT (2 equiv), 
iPr2EtN (2 equiv) in DMF (0.001 M), RT. Bond formed in macrocyclisation indicated in 
red; peptides were quantified by analytical HPLC by integration of the corresponding 
UV signal at 280 nm (see ESI).
Oxetane modified cyclic peptides: scope and limitations
To test the generality of these initial findings, the head-to-
tail cyclisation of a variety of oxetane modified substrates was 
studied and the isolated yields compared with those for the 
unmodified systems (Figure 3). Oxetane introduction clearly 
leads to appreciable improvements across a range of ring sizes 
as illustrated for tetrapeptides 9–12, pentapeptides 4 and 13 
and hexapeptide 14. OMCPs were obtained in yields ranging 
from 49-65% whereas all yields for the control systems were 
substantially lower (0-33%). In a striking illustration of the 
power of this new method, cyclisation to tetrapeptide 10 was 
achieved in 54% yield in the presence of the oxetane 
modification, however cyclodimerisation to octapeptide was 
the predominant reaction pathway (20%) for the unmodified 
system. The successful formation of 12 containing an alanine 
modified residue confirms that this methodology is not simply 
limited to glycine substitution. Generally, DEPBT was favoured 
as the activating agent as it gave efficient cyclisations and 
minimised formation of difficult to separate diastereomers 
(e.g. 13: DEPBT: 51%, d.r. >95:5; PyBOP: 64%, d.r. 3:1) arising 
from epimerisation at the C-terminus prior to cyclisation. In 
some instances, impurities derived from the DEPBT reagent 
proved hard to remove, in which case PyBOP was used as an 
alternative.
Figure 3 Oxetane modified cyclic peptides by head-to-tail macrocyclisation.a,b
a Reaction conditions: DEPBT (2 equiv), iPr2EtN (2 equiv), DMF (0.001 M), RT. b Bond 
formed in macrocyclisation indicated in red; yield in parenthesis for the cyclisation of 
linear peptide with C=O rather than oxetane in backbone. c PyBOP as activator. d 
Product isolated as the dimeric octapeptide. e DEPBT: 51%, d.r. >95:5; PyBOP: 64%, d.r. 
3:1. f DMTMM tetrafluoroborate as activator. Data taken from ref 13.
Next, the synthesis of OMCPs by SPPS techniques was 
examined. In this way, it is possible to circumvent the need to 
purify any of the intermediates, simplifying and accelerating 
the process and potentially enabling automation. This was 
realised through the synthesis of cyclic tetrapeptide 18 in an 
impressive 39% yield from commercial H-Trp(Boc)-2-ClTrt (15) 
(Scheme 4). First, the linear peptide 17 was prepared from 15, 
16 and Fmoc-Leu-OH using Fmoc/tBu SPPS,11a cleaved from the 
resin using TFE then cyclised to 18 using DEPBT conditions and 
purified by column chromatography. Macrocycles 19-21 based 
on different ring sizes were readily made through further 
generalisation of this SPPS approach (Figure 4 and ESI).  
Scheme 4 Synthesis of oxetane modified cyclic peptide 18 by SPPS. Reaction conditions: 
(a) 16 (2 equiv), HATU (1.9 equiv), iPr2EtN (4.0 equiv), DMF, 2-4 h, double coupling; (b) 
20% piperidine, DMF, 20 min; (c) Fmoc-Leu-OH (5.0 equiv), HATU (4.9 equiv), iPr2EtN 
(10 equiv), DMF, 1 h; (d) 20% piperidine, DMF, 20 min; (e) TFE/CH2Cl2 (1:4), 3 × 1 h; (f) 
DEPBT (2.0 equiv), iPr2EtN (2.0 equiv), DMF (0.001 M), 64 h.
Figure 4 Additional oxetane-modified macrocycles made using SPPS.a,b
a Overall yield from first resin-bound amino acid including final RP-HPLC purification. 
For full details, see ESI. b Bond formed in macrocyclisation indicated in red.
Macrocyclisations not involving head-to-tail ring closure 
have also been examined. Specifically, the formation of 
disulphide containing macrocycles through oxidative 
cyclisation of cysteine side chains has been explored (Scheme 
5). Treatment of 2, whose synthesis was described in Scheme 
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3, with iodine provided the 17-membered macrocycle by way 
of trityl deprotection and disulphide bond formation. Further 
reaction with TFA in the presence of the cation scavenger 
triisopropylsilane (TIS) facilitated removal of all the side chain 
protecting groups providing 22 after reverse-phase HPLC 
purification. Importantly, the four-membered oxetane ring 
survives the strongly acid conditions required to globally 
deprotect the side-chains including the arginine Pbf group. 
Smaller 11- and 14-membered macrocycles 23 and 24 were 
also conveniently produced in good yields using this 
methodology.
Scheme 5  Oxetane modified cyclic peptides by disulphide bond formation. Reagents 
and conditions: (a) I2 (3.0 equiv), MeOH, 1 h; (b) 70% TFA / 20% CH2Cl2 / 10% TIS, 2.5 h. b 
Bond formed in macrocyclisation indicated in red. c TFA step omitted; yield in 
parenthesis for the cyclisation of linear peptide with C=O rather than oxetane in 
backbone. d Data taken from ref 14.
Comparison with other amino acid modifications
To understand how significant these improvements are in 
the broader context of peptide macrocyclisation, a series of 
alternative modifications were made to the central G residue 
of LAGAY and the efficiencies of the ring closures compared. N-
Methyl glycine, 2-methylalanine (Aib), ethylenediamine, 
dimethylethylenediamine and -alanine were all introduced in 
place of the glycine (Scheme 6). These modifications could 
improve cyclisation efficiency by: (i) increasing the 
conformational flexibility of the peptide backbone by deletion 
of one of the amide bonds; (ii) enlarging the size of the 
macrocycle by introduction of an additional methylene group; 
(iii) bringing the reacting ends closer together by favouring the 
cis-amide conformation; or (iv) introducing a potentially 
beneficial Thorpe-Ingold effect. In fact, only the oxetane 
modification led to marked improvement in isolated yield of 
the derived cyclic peptides, suggesting that oxetane 
introduction is particularly beneficial.
Scheme 6 Synthesis of cLAGAY and impact of modifications on cyclisation.
Macrocyclisation to pentapeptide 13 by formation of all 
four possible amide bonds was examined to see whether the 
location of the oxetane relative to the amide bond being 
formed is important (Figure 5). The yields were compared with 
those obtained making pentapeptide 25 by the same 
disconnections. This approach removes inherent differences in 
cyclisation efficiency associated with amide bond formation 
between different amino acid residues. For all four pairs of 
cyclisation studied, the oxetane modified system 
outperformed the C=O system leading to higher product 
yields. However, larger improvements are seen when the 
modification is more centrally located along the precursor 
backbone.
Figure 5 Macrocyclisation efficiency as a function of location of oxetane relative to 
forming amide bond.a,b
a Reaction conditions: DEPBT (2 equiv), iPr2EtN (2 equiv), DMF (0.001 M), RT, 24 h. b 
Average of two runs. c Taken from ref 12.
Structural impact of oxetane modification 
To understand why oxetane incorporation improves the 
macrocyclisations, we undertook solution-state NMR studies 
on the linear cyclisation precursor LAGAY and its oxetane 
modified variant. In order to accurately mimic the active ester 
intermediate without the effect of zwitterion formation, which 
may alter the solution conformation, we chose to study the 
corresponding methyl esters: LAGAY-OMe and LAGOxAY-OMe. 
2D 1H-1H TOCSY and NOESY spectra were acquired as detailed 
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in the ESI in order to assign the 1H signals in both peptides and 
probe changes in conformation, especially near the site of 
modification. As shown in Figures 6a-b, oxetane modified 
LAGOxAY-OMe yielded a larger number of nuclear Overhauser 
enhancements (NOEs) than unmodified LAGAY-OMe. The 
observed NOEs were used to construct an NOE-connectivity 
map (Figure 6c) which summarises sequential (i.e. residue i to 
residue i+1) and medium-range NOEs that are commonly 
observed in -helices, -sheets, and turns.15 While sequential 
NOEs are observable in both peptides (dN, dNN, dN), 
medium-range NOEs are only observed in peptide LAGOxAY-
OMe containing the modification. Specifically, dNN (i, i+2) and 
dN (i, i+2) NOEs are clearly observed in the oxetane modified 
peptide between residues Gly3 and Tyr5 indicating their close 
proximity, data consistent with the formation of a turn. These 
NMR studies provide the first direct experimental evidence 
that the oxetane modification is indeed turn-inducing, and 
brings the peptide termini closer in space to facilitate efficient 
cyclisation (Scheme 6).       
Figure 6 NOESY spectra of LAGOxAY-OMe (black) and LAGAY-OMe (red) collected with 
a mixing time of 400 ms for samples containing 30 mM peptide solubilised in d6-DMSO. 
Both spectra were collected at 298 K at a field strength of 700 MHz. Panel (a) shows the 
amide to H H dipolar coupling in the fingerprint region, and panel (b) shows the 
sequential and medium-range amide proton coupling. Medium range NOEs are 
indicated by an asterisk and underlined. (c) NOE-connectivity maps of LAGOxAY-OMe 
and LAGAY-OMe based on NOE spectra collected with 250-800 ms mixing times. Each 
sequential and medium-range coupling is indicated on the left, and a bar is used to join 
the coupled residues if a coupling is observed.   
To gain insights into how oxetane modification impacts the 
structure of the derived cyclic peptides, molecular dynamics 
(MD) computer simulations with distance restraints derived 
from NMR experiments were carried out on cLAGAY (25) and 
cLAGOxAY (13) in DMSO. 2D 1H-1H NOESY spectra were used to 
compile a set of nuclear Overhauser enhancement (NOE) - 
derived experimental distance restraints that were 
incorporated into MD simulations using the CHARMM 
forcefield16 with modifications for the oxetane ring.7 All 
simulations were performed using the Gromacs 5.1.4 
simulation package.17 Each cyclic peptide was simulated for 
100 ns in DMSO at 500 K and from this trajectory five distinct 
conformations of each peptide were selected for a further 100 
ns at 300 K. For these small, relatively rigid peptides, 500 ns 
total simulation time was sufficient for the simulations to 
converge, given that no new structural information was 
obtained after ~320 ns. 
Figure 7 (a) NOE-restrained Molecular Dynamics simulations of cLAGAY (25 in cyan) and 
oxetane modified cLAGOxAY (13 in green). For each, a total of 10 representative 
structures are overlaid. (b) Peptide backbones of 13 and 25 with side-chains omitted 
for clarity. For 13, intramolecular H-bond is indicated (yellow dots). (c) Ramachandran 
plots showing dihedral angles 𝜓 against 𝜙 for the amino acid residues within 13 and 25.
Cluster analysis was performed on 12500 structures 
extracted from the trajectories at 40 ps intervals. Five and four 
distinct structures were found for peptides 25 and 13 
respectively, with the first three clusters representing ≥99.9% 
of the entire trajectory for both peptides. The trajectories 
were dominated by conformations belonging to a single 
cluster that represented 93.7% and 99.1% of the total 
population of 25 and 13, respectively (see ESI). Ten 
representative structures from the dominant cluster of each 
peptide are overlaid in Figure 7a. The cluster analysis indicates 
that the backbones of both structures have little 
conformational flexibility (as expected for small cyclic 
peptides), but that the OMCP is slightly more rigid. H-bond 
analysis revealed that the unmodified cyclic peptide 25 did not 
form any significant intra-peptide H-bonds whereas OMCP 13 
was characterised by a H-bond with 86.3% occupancy between 
the NH group of Leu1 and the O atom of Ala4 (see Figure 7b). 
The backbones of 25 and 13 in their dominant configurations 
are shown overlaid in Figure 7b. Oxetane introduction only 
alters the backbone conformation of residues in proximity to 
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the modification itself. In this case, an inversion of the amide 
bond between Ala4 and Tyr5 arises on oxetane introduction, 
which allows the structure to be stabilised by an intra-peptide 
H-bond across the macrocycle. Ramachandran plots, showing 
the distribution of the 𝜙 and 𝜓 backbone dihedral angles of 
each residue and the entire peptide (averaged over the entire 
simulation trajectory), are presented in Figure 7c. The 
Ramachandran plots show that 13 explores less of the 𝜙/𝜓 
space than 25, which supports our observation above that 13 
is more rigid. The Ramachandran plots also highlight the effect 
of the oxetane introduction on the structure of the residues in 
proximity to the modification, with Gly3, Ala4 and Tyr5 shifting 
to different regions of 𝜙/𝜓 space following the introduction of 
the oxetane, which is in agreement with the visual 
representation of the backbone in Figure 7b.
Metalloprotease inhibition studies
Studies to explore the impact of oxetane modification on 
the biactivity of the derived cyclic peptides were undertaken. 
cCNGRC (26) is known to target Aminopeptidase N (APN), a 
transmembrane zinc-dependent metalloprotease involved in a 
variety of processes, including blood pressure regulation, cell 
migration, viral uptake, cell survival, and angiogenesis.18,19 
Both oxetane modified derivative 22 and cCNGRC (26) were 
examined for their inhibitory activity towards porcine APN 
using a spectrophotometric assay (Table 2).19 Although both 
compounds are rather weak inhibitors, the fact that similar 
IC50 values were observed for 22 and 26 suggests that the 
oxetane motif is an excellent bioisostere of the amide bond it 
replaces.
Table 2 Relative inhibitory effects of 22 and cCNGRC (26) against porcine 
Aminopeptidase N (APN).a
Entry Compound IC50 (M)
1 22 175
2 cCNGRC (26) 212b
3 bestatinc 4.1b
a APN and the substrate L-leucine-p-nitroanilide were incubated for 1 h in the presence 
of gradient concentrations of inhibitors and formation of the product p-nitroaniline 
measured reading absorbance at 405 nm. IC50 values were calculated from 
concentration−response curves (see ESI). b Values slightly lower than those reported in 
ref 19. c Positive control.
Conclusions
A new way to make small macrocyclic peptides has been 
discovered and evaluated. The approach relies on the 
introduction of an oxetane into the backbone of the cyclisation 
precursor. Two strategies for the assembly of these molecules 
were developed involving either chain elongation of the 
peptide by reaction with 3-(nitromethylene)oxetane, or 
alternatively through coupling preformed Fmoc-protected 
dipeptide building blocks containing this modification. The first 
is convenient for the insertion of glycine modifications, 
whereas the second is more general, being suitable for 
introduction of oxetane modified derivatives of other L-amino 
acids,10 and for integration with conventional SPPS methods.11a  
Oxetane incorporation led to improvements in all the 
head-to-tail cyclisations studied as assessed by isolated yields, 
reaction rates and analysis of product distributions. The 
method works across a range of ring sizes and enabled the 
synthesis of a range of cyclic tetra-, penta-, hexa- and 
heptapeptides. Major improvements in yields are seen using 
glycine modified residues, with levels of epimerisation and 
dimerisation significantly reduced. The extension of this 
method to other modified L-amino acids was demonstrated. It 
can also be applied to side-chain to side-chain 
macrocyclisations, specifically oxidative ring closure of cysteine 
residues by disulphide bond formation. As a tool to improve 
head-to-tail macrocyclisations, our evidence suggests that 
oxetane incorporation is superior to a number of other 
common backbone modifications. Importantly, OMCPs are 
compatible with the harsh acidic conditions needed to 
deprotect amino acid side chains.
A key question we sought to address in this study was why 
does oxetane introduction improve macrocyclisations? For 
maximum benefit, we have shown that the oxetane is best 
located centrally along the peptide backbone, an observation 
consistent with the hypothesis that this modification is turn-
inducing.7 Moreover, using solution-state NMR spectroscopy, 
we have obtained the first direct experimental evidence that 
oxetane introduction induces a turn in the peptide backbone, 
through the observation of dNN (i, i+2) and dN (i, i+2) NOEs. 
The formation of a turn presumably helps bring the termini 
closer together enabling the macrocyclisation. 
To be useful in drug discovery programmes as well as being 
easy to make, OMCPs must also have useful properties. 
Intuitively, one might expect oxetane introduction to only alter 
the backbone configuration of the cyclic peptide close to the 
site of modification. Indeed, this was borne out in detailed 
NOE-restrained MD simulations conducted on 13. The full 
retention of bioactivity of 22 relative to cCNGRC suggests that 
the replacement of a C=O amide bond by an oxetane ring has 
little impact on binding, making it a viable bioisosteric 
replacement. Next steps will involve a fuller assessment of the 
properties of OMCPs and their application in drug discovery 
programmes.  
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